DESIGN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.78 USD | +0.53% |
|
+2.16% | +42.64% |
| Mar. 20 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
| Mar. 20 | Sector Update: Health Care Stocks Down Wednesday Afternoon | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 214M |
|---|---|---|---|---|---|
| Net income 2024 * | -73M | Net income 2025 * | -87M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 231M | Net cash position 2025 * | 168M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.99
x | P/E ratio 2025 * |
-2.59
x | Employees | 58 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.33% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.53% | ||
| 1 week | +2.16% | ||
| Current month | -6.20% | ||
| 1 month | -6.20% | ||
| 3 months | +60.85% | ||
| 6 months | +87.13% | ||
| Current year | +42.64% |
1 week
3.51
3.97
1 month
3.454.15
Current year
2.254.15
1 year
1.948.47
3 years
1.9429.16
5 years
1.9450.50
10 years
1.9450.50
| Managers | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CEO | Chief Executive Officer | 54 | 17-12-17 |
Sean Jeffries
COO | Chief Operating Officer | 44 | 20-12-31 |
Jae B. Kim
CTO | Chief Tech/Sci/R&D Officer | 55 | 22-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CEO | Chief Executive Officer | 54 | 17-12-17 |
John Schmid
BRD | Director/Board Member | 60 | 20-10-31 |
Simeon George
BRD | Director/Board Member | 46 | 20-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 3.78 | +0.53% | 108,094 |
| 24-04-25 | 3.76 | +3.01% | 217,768 |
| 24-04-24 | 3.65 | -0.27% | 192,880 |
| 24-04-23 | 3.66 | -5.91% | 161,666 |
| 24-04-22 | 3.89 | +5.14% | 248,707 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3.78
USD
Average target price
4.667
USD
Spread / Average Target
+23.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +42.64% | 214M | |
| +1.51% | 42.75B | |
| +49.17% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- DSGN Stock
